Health Care • Medical/Dental Instruments
$10.69 ▲ +0.13
(+1.23%)
MKT CAP: $342.7M • VOL: 1.25M
52W L $8 52W H $20
CLPT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $37.0M | $31.4M | $24.0M |
| YoY Revenue Growth % | +17.8% | +31.0% | — |
| Gross Profit | $22.7M | $19.1M | — |
| Gross Margin % | 61.4% | 60.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$24.2M | -$19.7M | -$22.4M |
| Operating Margin % | -65.4% | -62.9% | -80.0% |
| Net Income (GAAP) | -$25.5M | -$18.9M | -$22.1M |
| EBITDA (Normalized) | -$23.7M | -$19.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$23.9M | -$8.9M | -$13.7M |
| Capital Expenditures (CapEx) | $522.0K | $275.0K | — |
| Free Cash Flow (FCF) | -$24.4M | -$9.2M | -$13.7M |
| FCF Margin % | -66.1% | -29.4% | -57.3% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $45.9M | $20.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $28.0M | $25.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CLPT.